talnetant
Small moleculeexperimental
Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several functions. Its use as a potential antipsychotic drug for the treatment of schizophrenia has also been discontinued. — Wikipedia
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2002 (NCT00049946)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Neurokinin 3 receptorANTAGONIST
TACR3 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@H](NC(=O)c1c(O)c(-c2ccccc2)nc2ccccc12)c1ccccc1- Mol. weight
- 382.46 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTalnetant ↗
- ChEMBLCHEMBL10188 ↗
Also known as
- n-(alpha-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide
- sb-2234
- sb-2234
- sb 223412
- sb-223412
- sb-223412
- sb-223412
- talnetant
- talnetant
- talnetant
- talnetant
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00103727 | Phase 2 | Dec 1, 2004 | GlaxoSmithKline |
| NCT00300963 | Phase 2 | Dec 1, 2004 | GlaxoSmithKline |
| NCT00101985 | Phase 2 | Oct 1, 2004 | GlaxoSmithKline |
| NCT00049946 | Phase 2 | Oct 1, 2002 | GlaxoSmithKline |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 4 | 4 | 1 | 2002 |
1 organizations
Page 1 / 1